JP2017506233A - クレアチン、ω−３脂肪酸、及びシチコリンの組み合わせ - Google Patents

クレアチン、ω−３脂肪酸、及びシチコリンの組み合わせ Download PDF

Info

Publication number
JP2017506233A
JP2017506233A JP2016550629A JP2016550629A JP2017506233A JP 2017506233 A JP2017506233 A JP 2017506233A JP 2016550629 A JP2016550629 A JP 2016550629A JP 2016550629 A JP2016550629 A JP 2016550629A JP 2017506233 A JP2017506233 A JP 2017506233A
Authority
JP
Japan
Prior art keywords
creatine
citicoline
composition
omega
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016550629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506233A5 (enExample
Inventor
ペリー レンショー
ペリー レンショー
デボラ ユルゲラン−トッド
デボラ ユルゲラン−トッド
Original Assignee
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー オブ ユタ リサーチ ファウンデーション, ユニヴァーシティー オブ ユタ リサーチ ファウンデーション filed Critical ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Publication of JP2017506233A publication Critical patent/JP2017506233A/ja
Publication of JP2017506233A5 publication Critical patent/JP2017506233A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/187—Eicosapentaenoic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/1874—Linolenic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A23V2250/306—Creatine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
JP2016550629A 2014-02-07 2015-02-06 クレアチン、ω−３脂肪酸、及びシチコリンの組み合わせ Pending JP2017506233A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937328P 2014-02-07 2014-02-07
US61/937,328 2014-02-07
PCT/US2015/014856 WO2015120299A1 (en) 2014-02-07 2015-02-06 Combination of creatine, an omega-3 fatty acid, and citicoline

Publications (2)

Publication Number Publication Date
JP2017506233A true JP2017506233A (ja) 2017-03-02
JP2017506233A5 JP2017506233A5 (enExample) 2018-03-22

Family

ID=53778486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550629A Pending JP2017506233A (ja) 2014-02-07 2015-02-06 クレアチン、ω−３脂肪酸、及びシチコリンの組み合わせ

Country Status (6)

Country Link
US (2) US10058552B2 (enExample)
EP (1) EP3102227A4 (enExample)
JP (1) JP2017506233A (enExample)
KR (1) KR20160137528A (enExample)
CN (1) CN106102765A (enExample)
WO (1) WO2015120299A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058552B2 (en) 2014-02-07 2018-08-28 University Of Utah Research Foundation Combination of creatine, an omega-3 fatty acid, and citicoline

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11160982B2 (en) * 2017-07-05 2021-11-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating post-traumatic stress disorder in patients via renal neuromodulation
KR102269106B1 (ko) 2017-11-20 2021-06-24 주식회사 엘지화학 배터리 파워 한계 값 제어 방법
EP3563830A1 (en) 2018-05-03 2019-11-06 Commissariat à l'énergie atomique et aux énergies alternatives Micro-emulsion containing creatine fatty ester, method for preparing said micro-emulsion and uses thereof
KR102141737B1 (ko) * 2018-10-23 2020-08-05 이화여자대학교 산학협력단 크레아틴 및 타우린의 혼합물을 함유하는 우울장애 및 불안장애의 치료용 약학적 조성물
EP3732995A1 (en) * 2019-04-30 2020-11-04 Commissariat à l'énergie atomique et aux énergies alternatives Composition containing creatine fatty ester for use in medicine
EP4522145A1 (en) * 2022-05-12 2025-03-19 AlzChem Trostberg GmbH Composition comprising creatine for use in the treatment of post viral fatigue syndrome
IT202300026181A1 (it) * 2023-12-06 2025-06-06 Hope S R L Potenziata composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi quali parkinson e halzheimer

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503743A (ja) * 1996-10-11 2001-03-21 スコティア ホールディングズ ピー エル シー エイコサペンタエン酸および／またはステアリドン酸を含む治療用薬剤
US20020019364A1 (en) * 2000-03-16 2002-02-14 Renshaw Perry F. Compounds for the treatment of psychiatric or substance abuse disorders
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
JP2009532406A (ja) * 2006-04-06 2009-09-10 アルツケム トロストベルク ゲゼルシャフト ミット ベシュレンクテル ハフツング クレアチン、クレアチン一水和物、またはグアニジノ酢酸の製造方法
JP2010502611A (ja) * 2006-08-28 2010-01-28 マサチューセッツ インスティテュート オブ テクノロジー Ｃｄｐ−コリンを含有する組成物およびその使用法
US20110274680A1 (en) * 2009-10-02 2011-11-10 Mazed Mohammad A Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases
JP2013526865A (ja) * 2010-05-13 2013-06-27 ニトロメガ コーポレーション ニトロ脂肪酸、神経保護および／または認識減退の抑制
US20130324609A1 (en) * 2010-10-08 2013-12-05 University Of Utah Research Foundation Depression disorder therapeutics with creatine analogs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19929995B4 (de) 1999-06-30 2004-06-03 Skw Trostberg Ag Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
ATE457726T1 (de) * 2002-06-19 2010-03-15 Nutricia Nv Nahrungs- oder pharmazeutische zusammensetzungen zur erhöhung der creatin-antwort von organismen
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7776915B2 (en) 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
US20130281410A1 (en) 2010-05-13 2013-10-24 University Of Utah Research Foundation Methods for the treatment of psychiatric disorders
KR20160137528A (ko) 2014-02-07 2016-11-30 유니버시티 오브 유타 리서치 파운데이션 크레아틴, 오메가-3 지방산 및 시티콜린의 조합

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503743A (ja) * 1996-10-11 2001-03-21 スコティア ホールディングズ ピー エル シー エイコサペンタエン酸および／またはステアリドン酸を含む治療用薬剤
US20020019364A1 (en) * 2000-03-16 2002-02-14 Renshaw Perry F. Compounds for the treatment of psychiatric or substance abuse disorders
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
JP2009532406A (ja) * 2006-04-06 2009-09-10 アルツケム トロストベルク ゲゼルシャフト ミット ベシュレンクテル ハフツング クレアチン、クレアチン一水和物、またはグアニジノ酢酸の製造方法
JP2010502611A (ja) * 2006-08-28 2010-01-28 マサチューセッツ インスティテュート オブ テクノロジー Ｃｄｐ−コリンを含有する組成物およびその使用法
US20110274680A1 (en) * 2009-10-02 2011-11-10 Mazed Mohammad A Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases
JP2013526865A (ja) * 2010-05-13 2013-06-27 ニトロメガ コーポレーション ニトロ脂肪酸、神経保護および／または認識減退の抑制
US20130324609A1 (en) * 2010-10-08 2013-12-05 University Of Utah Research Foundation Depression disorder therapeutics with creatine analogs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF PSYCHIATRY, vol. 163, no. 10, JPN6018039872, 2006, pages 1840 - 1841, ISSN: 0004043792 *
ANAL.BIOCHEM., vol. 350, no. 1, JPN6018039875, 2006, pages 113 - 119, ISSN: 0004043794 *
J.NEUROCHEM., vol. 74, no. 5, JPN6018039873, 2000, pages 1968 - 1978, ISSN: 0004043793 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058552B2 (en) 2014-02-07 2018-08-28 University Of Utah Research Foundation Combination of creatine, an omega-3 fatty acid, and citicoline

Also Published As

Publication number Publication date
EP3102227A4 (en) 2017-09-27
CN106102765A (zh) 2016-11-09
US20180263983A1 (en) 2018-09-20
WO2015120299A1 (en) 2015-08-13
EP3102227A1 (en) 2016-12-14
US10058552B2 (en) 2018-08-28
US20170165264A1 (en) 2017-06-15
KR20160137528A (ko) 2016-11-30
US10265317B2 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
US10265317B2 (en) Combination of creatine, an omega-3 fatty acid, and citicoline
AU2022283769B2 (en) Neuroactive steroids, compositions, and uses thereof
JP6842206B2 (ja) Ｒ−ケタミンおよびその塩の医薬品としての応用
Gareri et al. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives
US8575219B2 (en) Compounds for the treatment of psychiatric or substance abuse disorders
Offenbaecher et al. Current trends in neuropathic pain treatments with special reference to fibromyalgia
US20130281401A1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
US20120046302A1 (en) Methods of treating cns disorders
US20130324609A1 (en) Depression disorder therapeutics with creatine analogs
RS65530B1 (sr) Derivati karbamoil cikloheksana za lečenje poremećaja iz spektra autizma
WO2015089503A2 (en) Methods of treating brain disorders or identifying biomarkers related thereto
US20130295203A1 (en) Methods and compositions for the treatment of neuropsychiatric disorders
CN120437129A (zh) 组合物在制备用于改善认知能力方面的药物中的用途
JP2025121388A (ja) 認知機能を改善するための薬物を調製するための組成物の使用
Kocsis et al. SELECTIVE DOPAMINE D4 RECEPTOR ACTIVATION SHIFTS THE BALANCE BETWEEN CORTICO-HIPPOCAMPAL DELTA AND THETA OSCILLATIONS IN AWAKE FREELY MOVING RATS
CN101366720A (zh) 多烯磷脂酰胆碱治疗认知功能障碍的药物用途
Herrero et al. Treatment of Depressive Episodes
Leonard Neuropsychopharmacology: Changing the Face of Psychotropic Drug Discovery
Malik et al. P1. 047 Effects of green tea on haloperidol-induced anxiety, tardive dyskinesia and central serotonin dopamine metabolism: a model study
Sader-Mazbar et al. P1. 049 Glial monoamine oxidase participates in deamination of dopamine formed from L-dopa in a rat model of Parkinsonian striatum
Martin Robert Hendren University of California
Lang Basal Ganglia Structure and the Effects of Neuroleptic Treatment in Schizophrenia
Lachance P1. 046 Depression in Parkinson's disease patients: the role of the clinical nurse specialist to improve the quality of life
JP2007512289A (ja) 不安処置のための（＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール
CN103747681A (zh) 有限认知损害的治疗方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190318

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190530

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190930

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20191021

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20191021

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200720

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201118

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210405

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210513

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210513